Michael M. Altaweel

A Phase II Randomized Double-Masked Trial of Pegaptanib, an Anti–Vascular Endothelial Growth Factor Aptamer, for Diabetic Macular Edema

Emmett T. Cunningham, Anthony P. Adamis, Michael M. Altaweel et al. · Ophthalmology · 2005 · 590 citations

Ocular Disease, Ophthalmology, Diabetes +6

Genetic variants near <i>TIMP3</i> and high-density lipoprotein–associated loci influence susceptibility to age-related macular degeneration

Wei Chen, Dwight Stambolian, Albert O. Edwards et al. · Proceedings of the National Academy of Sciences · 2010 · 511 citations · Full text

Collaborative Ocular Oncology Group Report Number 1: Prospective Validation of a Multi-Gene Prognostic Assay in Uveal Melanoma

Michael D. Onken, Lori A. Worley, Devron H. Char et al. · Ophthalmology · 2012 · 496 citations · Full text

Ocular Disease, Oncology, Uveal Melanoma +10

Randomized Comparison of Systemic Anti-inflammatory Therapy Versus Fluocinolone Acetonide Implant for Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment Trial

John H. Kempen, Michael M. Altaweel, Janet T. Holbrook et al. · Ophthalmology · 2011 · 325 citations · Full text

Rheumatology, Ophthalmology, Surgery +3

Changes in Retinal Neovascularization after Pegaptanib (Macugen) Therapy in Diabetic Individuals

Michael M. Altaweel, ET Cunningham, Davis et al. · Ophthalmology · 2005 · 249 citations

Diabetic Retinopathy, Ocular Disease, Ophthalmology +9